Scientists investigated the recommended dose for expansion of siremadlin, a p53-MDM2 inhibitor, in patients with wild-type TP53 advanced solid or hematologic cancers.
[Clinical Cancer Research]
Sorry, but the selected Zotpress account can't be found.